Microneedle assembly formulation for skin treatment
View Patent ↗A problem to be solved of the present invention is to provide a drug formulation and a method of administering an active ingredient which allow the active ingredient to be delivered evenly into the site of action in the skin with high efficiency while ensuring stability of the active ingredient over a long time, and which are easily handled and are less stressful for patients. Mean for solving the problem is a microneedle assembly formulation for skin treatment comprising a platform and a plurality of conical or pyramidal microneedles formed on the platform containing a base composed of a bio-soluble and thread-forming polymer substance and an objective substance retained in the base, wherein the objective substance is a substance effective for prevention or treatment of skin senescence, or treatment of skin scar.
1. A microneedle assembly formulation for use in prevention or treatment of one or more target symptoms selected from the group consisting of skin aging, UV-damaged skin, hypertrophic scar, atrophic scar, keloids, acne scar, hair loss, suture wound, burn wound, ulcer, bedsore, diabetic ulcer or a disease requiring angiogenesis comprising a platform and a plurality of conical or pyramidal microneedles formed on the platform,
wherein each of the microneedles contains a base composed of a bio-soluble and thread-forming polymer substance and an objective substance retained in the base;
wherein each of the microneedles has a first layer forming a tip part containing the objective substance and a second layer forming a bottom part not containing the objective substance;
wherein the objective substance is present in an amount from 0.11 to 56 μg/cm 2 of the microneedle assembly;
wherein the objective substance is basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), or a nucleic acid and a plasmid encoding the gene thereof;
wherein the first layer has a length such that the tip part containing the objective substance is configured to deliver the objective substance to a dermal layer of skin but not to an epidermal layer of skin, and
wherein the microneedle assembly formulation is configured to prevent or treat the one or more target symptoms without causing pigmentation in the skin to occur.
2. The microneedle assembly formulation according to claim 1 , wherein a substance constituting the base further comprises at least one selected from a group consisting of chondroitin sulfate and salts thereof, dextran, hyaluronic acid and salts thereof.
3. A method of administrating a substance effective for prevention or treatment of one or more target symptoms selected from the group consisting of skin aging, UV-damaged skin, hypertrophic scar, atrophic scar, keloids, acne scar, hair loss, suture wound, burn wound, ulcer, bedsore, diabetic ulcer or a disease requiring angiogenesis, wherein the method comprises a step of applying a surface on a microneedle-existing side of the microneedle assembly formulation for skin treatment according to claim 1 to an affected area targeted for prevention or treatment of the one or more target symptoms, and applying a pressure force of 7 to 40 N to insert the microneedles through the skin into a body, wherein the first layer has a length such that the tip part containing the objective substance is configured to delivers the objective substance to a dermal layer of skin but not to an epidermal layer of skin.
4. The method according to claim 3 , further comprising applying secondary pressurization force of 0.5 to 2.5 N to the microneedle assembly that is inserted through the skin into the body.
5. The microneedle assembly formulation according to claim 1 , wherein the platform is a porous plate of plastics or a molded product consisting of water-insoluble excipient for tablets.
6. The microneedle assembly formulation according to claim 1 , wherein the platform is a bilayer tablet composed of a molded layer made from water-insoluble excipient for tablets and a molded layer made from water-insoluble excipient for tablets and iron powder.
7. The microneedle assembly formulation according to claim 1 , wherein the microneedles exist on the platform in a density from 30 to 300 needles/cm 2 .
8. The microneedle assembly formulation according to claim 1 , wherein the first layer has an inserting-direction length of 233 μm or less.
9. A microneedle assembly formulation package comprising a push-through pack packaging container, the microneedle assembly formulation for skin treatment according to claim 1 contained in the push-through pack packaging container and an aluminum sheet put on an opening of the push-through pack packaging container, the push-through pack being sealed by pressurization and heating.
10. The microneedle assembly formulation according to claim 1 , wherein the second layer has an inserting-direction length of 220 μm or more and 400 μm or less.
11. The microneedle assembly formulation according to claim 1 , wherein the second layer has an inserting-direction length of 267 μm or more and 400 μm or less.